CLVS Clovis Oncology Inc.

CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

BOULDER, Colo.--(BUSINESS WIRE)--

First paragraph, second sentence of release should read: Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis’ results and business outlook in greater detail. (instead of Clovis’ senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis’ results and business outlook in greater detail.).

The updated release reads:

CLOVIS ONCOLOGY TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST WEBCAST CONFERENCE CALL ON AUGUST 8

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis’ results and business outlook in greater detail.

The conference call will be simultaneously webcast on the Clovis Oncology website , and a replay of the webcast will be available for 30 days.

Dial-in numbers for the conference call are as follows: US participants 888.440.4615 International participants 646.960.0682, conference ID: 2259685.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the US, Europe, and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops with partners diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit for more information, including additional office locations in the US and Europe.

EN
20/07/2022

Underlying

CLVSClovis Oncology Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clovis Oncology Inc.

 PRESS RELEASE
Free
CLVS Clovis Oncology...

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreem...

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the “Debtors”) have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) and will seek to sell their assets through a court supervised sales process. The Debtors have filed vario...

December 12, 2022 1 EN
 PRESS RELEASE
Free
CLVS Clovis Oncology...

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (...

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation titled, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy in mCRPC Associated with Homologous Recombination Deficiency (HRD)” is being presented by Alan H. Bryce, MD, chair of the Division of Hematology and Medical Oncology at the Mayo Clinic and co-principal investigator of the TRITON3 trial during the session titled, “Novel C...

October 27, 2022 1 EN
 PRESS RELEASE
Free
CLVS Clovis Oncology...

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Ra...

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286). Overall, in eleven patients treated in the first three dose cohorts, 177Lu-FAP-2286 demonstrated a manageable safety profile and enc...

October 17, 2022 1 EN
 PRESS RELEASE
Free
CLVS Clovis Oncology...

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoin...

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the Phase 3, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca monotherapy treatment achieved the primary endpoint of significantly improved radiographic progression-free survival (rPFS) by independent radiology review (IRR) compared with the control group, which consisted of physician’s choice of docetaxel, abiraterone acetate, or enzalutamide. Benefit was observed in both primary efficacy analyses of patients with chemotherapy-naïve metastatic castrati...

October 3, 2022 1 EN
 PRESS RELEASE
Free
CLVS Clovis Oncology...

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agr...

BOULDER, Colo. & PETACH TIKVA, Israel--(BUSINESS WIRE)-- and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopia’s lutetium-177 (177Lu) n.c.a. for use in the clinical development of FAP-2286, Clovis’ fibroblast activation protein (FAP)-targeting therapeutic candidate. FAP-2286 is the first peptide-targeted radionuclide therapeutic (PTRT) candidate directed against fibroblast activation protein undergoing clinical testing and is currently being investigated in the Phase 1/2 LuMIERE study for patients with advanc...

September 21, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch